No established body of evidence links mold exposure to breast cancer in humans. The concern is not baseless, though, because molds produce chemicals called mycotoxins, and a handful of these have properties in the lab that raise red flags for hormone-sensitive cancers. The gap between what happens inside a petri dish and what happens inside a person is wide, and for breast cancer specifically, the human data is remarkably thin. Understanding why researchers are still watching this space requires looking at which mycotoxins matter, what they do in cells, and why the jump from lab to real-world risk has been so hard to make.
Mycotoxins, Not Mold Itself, Are the Concern
When people ask whether mold causes cancer, they usually picture the dark patches on a bathroom wall or the fuzzy growth on old bread. Mold in that sense is a living fungus, and it is not the fungus itself that worries toxicologists. The worry is the toxic byproducts molds release as they grow. These byproducts, called mycotoxins, are small molecules that can contaminate grain, nuts, dried fruit, spices, coffee, and other foods. They can also become airborne in heavily contaminated buildings. Different mold species produce different mycotoxins, and only a subset of those have been studied for cancer-related effects.
Two mycotoxins dominate the conversation around cancer: aflatoxin B1 and zearalenone. Aflatoxin B1 is produced mainly by Aspergillus species and is one of the most potent known liver carcinogens in humans. Zearalenone comes from Fusarium molds and acts as an endocrine disruptor because it binds to estrogen receptors, the same receptors that drive many breast cancers. These two chemicals work through entirely different mechanisms, and their relevance to breast cancer is not the same.
Zearalenone and Estrogen Receptors
Zearalenone is the mycotoxin most directly relevant to breast cancer biology, and the reason is straightforward: it mimics estrogen. Zearalenone and its breakdown products bind to estrogen receptors and can trigger estrogen-like responses in cells. Because roughly two-thirds of breast cancers are driven by estrogen signaling, any compound that activates the same pathway at least deserves scrutiny.
In laboratory studies, zearalenone and its derivatives stimulate the growth of estrogen-receptor-positive human breast cancer cells (a line called MCF-7). That growth can be partially blocked by tamoxifen, a drug used in breast cancer treatment that competes for the estrogen receptor, confirming that the effect runs through the receptor rather than some unrelated pathway.1PubMed. Investigations on cellular proliferation induced by zearalenone and its derivatives in relation to the estrogenic parameters In breast cancer cells that lack estrogen receptors entirely (a line called MDA-MB-231), zearalenone has little to no growth-promoting effect, which reinforces the idea that the receptor is the key mediator.
Zearalenone has also been shown to act through at least two other signaling routes in breast cancer cells: a membrane-bound estrogen receptor called GPER and the MAPK signaling cascade, both of which are involved in cell growth and survival.2PubMed Central. Combined low-dose zearalenone and aflatoxin B1 on cell growth and cell-cycle progression in breast cancer MCF-7 cells This multi-pathway activity makes zearalenone more than a simple estrogen mimic. It alters the expression of several breast-cancer-related genes, at least in cell culture. The question is whether the doses people encounter in food are anywhere close to the concentrations used in these experiments, and the honest answer is that nobody has nailed that down for breast tissue.
Aflatoxin B1 and Its Unusual Relationship to Breast Cells
Aflatoxin B1 (AFB1) is classified as a Group 1 human carcinogen by the International Agency for Research on Cancer, but that classification rests almost entirely on liver cancer data. AFB1 causes cancer by damaging DNA: the body’s liver enzymes convert it into a reactive form that physically attaches to DNA, creating what toxicologists call a bulky adduct. If the cell’s repair machinery fails to fix that damage before the cell divides, the result can be a mutation.3PubMed. DNA damage checkpoint response to aflatoxin B1 This mechanism is well characterized in liver cells, where the relevant enzymes are abundant.
In breast cancer cells, AFB1 behaves differently. Lab experiments exposing MCF-7 cells to AFB1 found that it was actually cytotoxic, meaning it killed cells rather than promoting their growth. It triggered oxidative stress and ramped up inflammatory markers while suppressing certain immune-related genes.4PubMed. Effects of aflatoxin B1 on human breast cancer (MCF-7) cells: cytotoxicity, oxidative damage, metabolic, and immune-modulatory transcriptomic changes When researchers combined low doses of AFB1 and zearalenone together on breast cancer cells, the two mycotoxins produced an unexpected dynamic: zearalenone promoted cell growth while AFB1 counteracted it.2PubMed Central. Combined low-dose zearalenone and aflatoxin B1 on cell growth and cell-cycle progression in breast cancer MCF-7 cells
This does not mean AFB1 protects against breast cancer. Killing cells through oxidative damage and inflammation is not the same as being harmless. Chronic inflammation is itself a recognized driver of cancer development. But it does suggest that AFB1’s carcinogenic mechanism, which works so effectively in the liver, does not translate cleanly to breast tissue. The enzymes that activate AFB1 into its DNA-damaging form are concentrated in the liver, and breast tissue has far less of that enzymatic machinery.
What the Human Studies Actually Show
This is where the evidence gets uncomfortably thin. A systematic review of epidemiological studies on mycotoxin exposure and cancer risk found that only two case-control studies, both conducted in Africa, had investigated the relationship between zearalenone and breast cancer in real people. Those two studies produced conflicting results.5PubMed. Mycotoxin exposure and human cancer risk: A systematic review of epidemiological studies That is the entirety of the direct epidemiological evidence connecting any mycotoxin to breast cancer specifically.
For mycotoxins and cancer more broadly, the picture is only slightly better. A meta-analysis pooling available studies found no significant overall association between mycotoxin-linked mutations and cancer risk, although some individual studies did confirm a link with primary liver cancer.6PubMed Central. Mycotoxin-Linked Mutations and Cancer Risk: A Global Health Issue The authors noted that most of the positive associations came from experimental (lab-based) studies, not from population-level data, and called for more epidemiological research to guide public health decisions.
The scarcity of human studies does not mean the risk is zero. It means the risk, if it exists, has not been measured in a way that meets the bar for scientific confidence. Breast cancer is influenced by dozens of factors simultaneously, and isolating the contribution of low-level mycotoxin exposure from dietary contamination is extraordinarily difficult. Researchers would need large populations with well-characterized mycotoxin exposure over years, and those studies have simply not been done for breast cancer.
Indoor Mold and the Inhalation Question
Many people asking whether mold causes breast cancer are thinking about the mold in their home, not the mycotoxins in their cereal. Indoor mold exposure is a legitimate health concern, but the evidence tilts heavily toward respiratory problems, allergies, and asthma rather than cancer.
A critical review of the health effects of inhaled mycotoxins found that while high levels of exposure or direct contact with mycotoxin-producing molds can cause measurable effects in both animals and humans, the concentrations found in most mold-contaminated indoor environments are unlikely to produce those effects.7PubMed. Health effects of mycotoxins in indoor air: a critical review The keyword there is “most.” Severely water-damaged buildings with massive mold growth are a different situation than a small patch of mildew in a shower.
Molds also release volatile organic compounds, the chemicals responsible for that musty smell. Researchers have shown that two common fungal volatiles can damage bone marrow stromal cells in the lab, disrupting cell membranes and potentially impairing immune function.8PubMed Central. The effects of fungal volatile organic compounds on bone marrow stromal cells Bone marrow stromal cells are important for immune cell development, so this finding points toward immune suppression rather than direct tumor formation. It’s the kind of result that opens a research thread, not the kind that closes the case.
No study has drawn a line from breathing indoor mold to developing breast cancer. The biological plausibility is low: the doses of mycotoxins in typical indoor air are orders of magnitude below what produces effects in cell culture, and the route of exposure (inhaling tiny amounts) is very different from what most toxicology experiments model.
Occupational Exposure Tells a More Interesting Story
While indoor mold at home is an unlikely cancer risk, occupational exposures are a different category. A large Canadian case-control study looked at breast cancer risk across dozens of job sectors and found that women who worked in agriculture had a modestly elevated risk. Women in jobs with potentially high exposure to carcinogens and endocrine disruptors for ten or more years had roughly 40 percent higher breast cancer risk overall.9Environmental Health: A Global Access Science Source / CDC Stacks. Breast Cancer Risk in Relation to Occupations with Exposure to Carcinogens and Endocrine Disruptors: A Canadian Case-Control Study
Agriculture stood out, but so did sectors that seemingly have nothing to do with mold: automotive plastics manufacturing, food canning, and metalworking all showed elevated risk. This is important context. The agricultural risk might partly reflect exposure to fungal contaminants and mycotoxins, but it likely also reflects pesticide exposure, hormonal disruption from other chemicals, or some combination of factors that are hard to separate. The study did not measure mycotoxin exposure directly. It measured job categories and cancer outcomes, which means mold-related chemicals are just one of many possible explanations for the agricultural signal.
The Epigenetic Angle
Beyond direct DNA damage and estrogen mimicry, mycotoxins can alter gene activity through a third route: epigenetic changes. These are modifications that don’t change the DNA sequence itself but change how genes are read and expressed. Reviews of the literature have identified several types of epigenetic alterations triggered by mycotoxin exposure, including changes in DNA methylation patterns, shifts in non-coding RNA profiles, and modifications to the histone proteins that package DNA.10PubMed. Multidimensional analysis of the epigenetic alterations in toxicities induced by mycotoxins11PubMed. Role of epigenetics in mycotoxin toxicity: A review
Epigenetic disruption is increasingly recognized as a contributor to cancer development in general. Abnormal methylation patterns, for instance, can silence tumor-suppressor genes or activate growth-promoting genes. For mycotoxins, the work has been done across multiple toxins (aflatoxin B1, zearalenone, ochratoxin A, deoxynivalenol, and others) and multiple cell types, but the breast-cancer-specific implications remain speculative. The fact that mycotoxins can fiddle with the epigenetic controls of cells is a reason to keep studying them, not a reason to conclude they cause breast cancer.
When Mycotoxins Show Up Together
Real-world exposure to mycotoxins almost never involves a single compound in isolation. Contaminated grain can carry aflatoxin B1, zearalenone, ochratoxin A, and several others simultaneously. This matters because combinations of toxins do not always behave the way you would predict from studying each one alone.
Research on the combined effects of three mycotoxins (beauvericin, enniatin B, and ochratoxin A) on breast cancer cells found that certain binary and triple combinations were more cytotoxic than any individual compound, producing synergistic rather than merely additive effects. Interestingly, the most sensitive cells in these experiments were not the breast cancer cells themselves but normal immune cells from peripheral blood, which were more susceptible to damage from all three mycotoxins and their combinations.12PubMed Central / Elsevier. Evaluating the combined and individual cytotoxic effect of beauvericin, enniatin B and ochratoxin a on breast cancer cells, leukemia cells, and fresh peripheral blood mononuclear cells
This adds another layer of complexity. If mycotoxin combinations preferentially damage immune cells, they could theoretically impair the body’s ability to detect and destroy early cancer cells, contributing to cancer risk indirectly rather than by initiating tumors. This is still firmly in the realm of hypothesis, but it illustrates why the “does mold cause cancer” question resists a simple yes or no.
What Happens to Mycotoxins in Your Gut
Some mycotoxins in food are chemically disguised. Plants can bind mycotoxins to sugar molecules or other compounds, creating what are called masked mycotoxins. These modified forms may not register on standard food safety tests, which is a regulatory headache. Research has shown that masked forms of zearalenone and trichothecene mycotoxins pass through the stomach and small intestine intact, resisting digestion, but are then efficiently broken down by gut bacteria in the large intestine.13PubMed. Masked trichothecene and zearalenone mycotoxins withstand digestion and absorption in the upper GI tract but are efficiently hydrolyzed by human gut microbiota in vitro
The gut bacteria liberate the original mycotoxin from its disguise, and in some cases may further convert it into metabolites whose toxicity is not yet fully characterized. This means that total mycotoxin exposure from food could be higher than what standard testing suggests. It also means that individual differences in gut bacteria composition could lead to different levels of actual exposure from the same contaminated meal. For zearalenone specifically, some of these gut-bacteria-generated metabolites may retain estrogen-receptor-binding activity, but the details and real-world significance of that are still under investigation.
Regulatory Limits and Practical Exposure
Governments worldwide set maximum allowable levels of mycotoxins in food. The European Union, for example, has some of the strictest limits, regulating aflatoxins, zearalenone, ochratoxin A, deoxynivalenol, and fumonisins in cereals, nuts, spices, and baby food. The United States FDA sets action levels primarily for aflatoxins. International bodies like the FAO and WHO coordinate guidelines and risk assessments.14PubMed Central. Mycotoxins in Food: Cancer Risks and Strategies for Control
These regulations are designed primarily around the risk of liver cancer from aflatoxins, which is the best-established mycotoxin-cancer link. Breast cancer has not been a driver of mycotoxin regulation because the evidence is not there to justify it. In wealthier countries with strong food safety systems, mycotoxin levels in the food supply are generally well below regulatory limits. The concern is greater in parts of sub-Saharan Africa and Southeast Asia, where hot and humid conditions promote mold growth on stored grain, food safety infrastructure is weaker, and dietary diversity is lower, meaning people may eat heavily contaminated staple foods day after day.
If you live in a country with functioning food safety regulation and eat a reasonably varied diet, your mycotoxin exposure is low. If you are concerned about mold on food at home, the standard advice still holds: discard visibly moldy bread, soft fruits, and cooked leftovers rather than cutting around the mold, because mycotoxins can spread invisibly beyond the visible growth. Hard cheeses and firm vegetables are exceptions where cutting away a generous margin around the mold is generally considered safe.
Why This Research Keeps Going Even Without a Clear Answer
The scientific interest in mycotoxins and breast cancer persists for a few reasons that are worth understanding. Breast cancer is the most common cancer in women worldwide, and its causes remain incompletely explained. Known risk factors like genetics, hormone replacement therapy, alcohol, and obesity account for a substantial share of cases, but a meaningful fraction occurs in women with no obvious risk factors at all. Environmental exposures, including low-level chronic chemical exposures, are suspected of filling part of that gap. Mycotoxins are among the environmental chemicals that have biologically plausible mechanisms for contributing to breast cancer, and zearalenone’s estrogen-receptor activity is one of the more compelling of those mechanisms.
The other reason is that mycotoxin exposure is nearly universal. Almost everyone eats trace amounts of these compounds regularly. Even in well-regulated food systems, detectable levels of aflatoxins, zearalenone, or deoxynivalenol show up in grain-based foods and animal products. If even a small chronic effect on breast cancer risk existed, the population-level impact could be meaningful simply because so many people are exposed. That is the logic driving continued research, even though the current evidence does not support a causal claim. Researchers investigating this area are not suggesting you should panic about mold. They are trying to determine whether a ubiquitous, low-grade exposure contributes a small piece to a complex disease, and that question remains genuinely open.